-
-
Use of Hip Protectors in Nursing Homes: Cluster Randomized Controlled Trial; Disclosing Unanticipated Outcomes and Medical Errors; Non-Invasive Positive Pressure Ventilation to Treat Respiratory Failure Resulting from Exacerbations of COPD
-
Eletriptan is the newest triptan to be approved for the treatment of migraine headaches. It marks the seventh entry into this crowded market.
-
Initiation of antihypertensive treatment involving ACE inhibitors in older subjects, particularly men, appears to lead to better outcomes than treatment with diuretic agents, despite similar reductions of blood pressure.
-
The metabolic syndrome affects more than 1 in 5 Americans and is increased substantially in Mexican Americans and by several modifiable lifestyle factors.
-
The findings of this study, which are consistent with the results of studies in animals, as well as in vitro and epidemiologic dietary studies, suggest that current levels of vitamin A supplementation and food fortification in many Western countries may need to be reassessed.
-
A randomized, diet-controlled interventional study demonstrates that moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels.
-
Low intensity warfarin therapy effectively prevents recurrent venous thromboembolism, according to a recent study in the New England Journal of Medicine.
-
On February 26th, the FDA approved a transdermal formulation of oxybutynin for the treatment of overactive bladder and urinary incontinence. Oxytrol Patch (Watson Pharmaceuticals) provides 3.9 mg/d and can be administered twice per week.
-
This population report investigated the prevalence of gluten sensitivity amongst a large cohort of patients with both sporadic and familial ataxia.